Your session is about to expire
← Back to Search
Radiopharmaceutical Diagnostic Imaging Agent
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor (POET-2 Trial)
Phase 3
Waitlist Available
Research Sponsored by Alseres Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial will evaluate if 123I-ALTROPANE® paired with SPECT imaging can provide a more accurate early diagnosis of Parkinson's than clinical diagnosis alone.
Eligible Conditions
- Parkinson's disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Parkinsonian SyndromesExperimental Treatment1 Intervention
Subjects with Parkinsonian Syndromes
Group II: Non-Parkinsonian SyndromesExperimental Treatment1 Intervention
Subjects with Non-Parkinsonian Syndromes
Find a Location
Who is running the clinical trial?
Alseres Pharmaceuticals, IncLead Sponsor
1 Previous Clinical Trials
54 Total Patients Enrolled